Inhibitory activity of hibifolin on adenosine deaminase- experimental and molecular modeling study

Adenosine deaminase (ADA) is an enzyme involved in purine metabolism. ADA converts adenosine to inosine and liberates ammonia. Because of their critical role in the differentiation and maturation of cells, the regulation of ADA activity is considered as a potential therapeutic approach to prevent malignant and inflammatory disorders. In the present study, the inhibitory activity of a plant flavonoid, hibifolin on ADA is investigated using enzyme kinetic assay and isothermal titration calorimetry. The inhibitory constant of hibifolin was found to be 49.92μM±3.98 and the mode of binding was reversible. Isothermal titration calorimetry showed that the compound binds ADA with binding energy of -7.21Kcal/mol. The in silico modeling and docking studies showed that the bound ligand is stabilized by hydrogen bonds with active site residues of the enzyme. The study reveals that hibifolin can act as a potential inhibitor of ADA.

[1]  J. Mallol,et al.  Moonlighting Adenosine Deaminase: A Target Protein for Drug Development , 2015, Medicinal research reviews.

[2]  P. Ramesh,et al.  A NEW FLAVONE METHYL ETHER FROM HELICTERES ISORA , 1995 .

[3]  F A Quiocho,et al.  Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. , 1991, Science.

[4]  Takayoshi Kinoshita,et al.  A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization. , 2004 .

[5]  F A Quiocho,et al.  Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity. , 1998, Biochemistry.

[6]  Ettore Novellino,et al.  Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. , 2009, Journal of medicinal chemistry.

[7]  R. Glazer Adenosine deaminase inhibitors: Their role in chemotherapy and immunosuppression , 2004, Cancer Chemotherapy and Pharmacology.

[8]  G. Cristalli,et al.  Functional residues at the active site of bovine brain adenosine deaminase , 1997, Biochemistry and molecular biology international.

[9]  J. Mallol,et al.  Human adenosine deaminase as an allosteric modulator of human A1 adenosine receptor: abolishment of negative cooperativity for [3H](R)‐pia binding to the caudate nucleus , 2008, Journal of neurochemistry.

[10]  M. Melzig Inhibition of Adenosine Deaminase Activity of Aortic Endothelial Cells by Selected Flavonoids , 1996, Planta medica.

[11]  F. Ciruela,et al.  Adenosine Deaminase Interacts with A1 Adenosine Receptors in Pig Brain Cortical Membranes , 1996, Journal of neurochemistry.

[12]  V. Valli,et al.  Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome , 2003, Critical care medicine.

[13]  T. Brady,et al.  A purification of adenosine deaminase from the superficial mucosa of calf intestine. , 1962, Biochimica et biophysica acta.

[14]  M. Hegen,et al.  Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. , 1996, Journal of immunology.

[15]  B. Mitchell,et al.  Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. , 1980, Blood.

[16]  Dong Wan Kim,et al.  Isolation and characterization of a novel adenosine deaminase inhibitor, IADA-7, from Bacillus sp. J-89 , 2009 .

[17]  N. Pfrogner Adenosine deaminase from calf spleen. I. Purificiation. , 1967, Archives of biochemistry and biophysics.

[18]  T. Kinoshita,et al.  Structural basis of compound recognition by adenosine deaminase. , 2005, Biochemistry.

[19]  V. Caiolfa,et al.  Adenosine deaminase-complexing protein from bovine kidney. Isolation of two distinct subunits. , 1988, The Journal of biological chemistry.

[20]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[21]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[22]  Thomas A. Halgren,et al.  Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996 .

[23]  T. Kinoshita,et al.  Crystallization and preliminary analysis of bovine adenosine deaminase. , 1999, Acta crystallographica. Section D, Biological crystallography.

[24]  M. Grever,et al.  Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. , 2000, Blood.

[25]  M. Wargovich,et al.  Inhibition of carcinogenesis by tea: the evidence from experimental studies. , 1997, Critical reviews in food science and nutrition.

[26]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.